Need Assistance?
  • US & Canada:
  • UK: +


* Please kindly note that our products are not to be used for therapeutic purposes and cannot be sold to patients.

Edotreotide is a substance used in the treatment and diagnosis of certain types of cancer.

Catalog number
CAS number
Molecular Formula
Molecular Weight
Size Price Stock Quantity
1 mg $299 In stock
5 mg $734 In stock
2-[4-[2-[[(2R)-1-[[(4R,7S,10S,13R,16S,19R)-10-(4-aminobutyl)-4-[[(2R,3R)-1,3-dihydroxybutan-2-yl]carbamoyl]-7-[(1R)-1-hydroxyethyl]-16-[(4-hydroxyphenyl)methyl]-13-(1H-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicos-19-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]-7,10-bis(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetic acid
Alternative CAS
DOTA-(Tyr3)-Octreotide; SMT-487; SMT 487; SMT487; DOTA-d-Phe1-Tyr3-octreotide; DOTA-TOC; DOTA0-Tyr3-octreotide; DOTATOC; [Tyr3]-octreotide; DOTA-TOC; DOTA-tyr(3)-octreotide; DOTATOC
Boiling Point
1723.7ºC at 760 mmHg
Store at -20°C
InChI Key
Canonical SMILES
1. New Insights in PRRT: Lessons From 2021
Rosa Lauretta, Alfonsina Chiefari, Marta Bianchini, Marialuisa Appetecchia, Marilda Mormando, Giulia Puliani Front Endocrinol (Lausanne) . 2022 Apr 5;13:861434. doi: 10.3389/fendo.2022.861434.
Peptide receptor radionuclide therapy (PRRT) using radiolabeled somatostatin analogs has been used for over two decades for the treatment of well-differentiated neuroendocrine tumors (NETs), and the publication of the NETTER-1 trials has further strengthened its clinical use. However, many aspects of this treatment are still under discussion. The purpose of this review is to collect and discuss the new available evidence, published in 2021, on the use of177Lu-Oxodotreotide (DOTATATE) or90Y-Edotreotide (DOTATOC) in adult patients with NETs focusing on the following hot topics: 1) PRRT use in new clinical settings, broaden its indications; 2) the short- and long-term safety; and 3) the identification of prognostic and predictive factors. The review suggests a possible future increase of PRRT applications, using it in other NETs, as a neoadjuvant treatment, or for rechallenge. Regarding safety, available studies, even those with long follow-up, supported the low rates of adverse events, even though 1.8% of treated patients developed a second malignancy. Finally, there is a lack of prognostic and predictive factors for PRRT, with the exception of the crucial role of nuclear imaging for both patient selection and treatment response estimation.
2. Edotreotide Gallium Ga-68
Edotreotide gallium Ga-68 (Ga 68 Dotatoc) is used for localization of somatostatin receptor positive neuroendocrine tumors. Labeling in the U.S. advises nursing mothers to pump and discard breastmilk for 8 hours after a dose.Mothers concerned about the level of radioactivity in their milk could ask to have it tested at a nuclear medicine facility at their hospital. When the radioactivity is at a safe level, she may resume breastfeeding. A method for measuring milk radioactivity and determining the time when a mother can safely resume breastfeeding has been published.[1]Nursing mothers should not work with radioactive substances used in PET scans in their workplace.[2]
3. 90Y-edotreotide for metastatic carcinoid refractory to octreotide
Yusuf Menda, Francoise Borson-Chazot, Lowell Anthony, Jean-Louis Baulieu, Al B Benson, Ashley B Grossman, Hakim Bouterfa, David L Bushnell Jr, Rodney J Hicks, M Sue O'Dorisio, Thomas M O'Dorisio, Katherine A Kacena, Stanislas A Pauwels, Eric Van Cutsem, Yong Li, Kjell Oberg, Mary Connolly, Norman LaFrance J Clin Oncol . 2010 Apr 1;28(10):1652-9. doi: 10.1200/JCO.2009.22.8585.
Purpose:Metastatic carcinoid is an incurable malignancy whose symptoms, such as diarrhea and flushing, can be debilitating and occasionally life-threatening. Although symptom relief is available with octreotide, the disease eventually becomes refractory to octreotide, leaving no proven treatment options. The goal of this study was to evaluate the clinical effect of using (90)Y-edotreotide to treat symptomatic patients with carcinoid tumors.Patients and methods:Patients enrolled had metastatic carcinoid, at least one sign/symptom refractory to octreotide, and at least one measurable lesion. Study treatment consisted of three cycles of 4.4 GBq (120 mCi) (90)Y-edotreotide each, once every 6 weeks.Results:Ninety patients were enrolled in the study. Using Southwest Oncology Group tumor response criteria, 67 (74.%) of 90 patients (95% CI, 65.4% to 83.4%) were objectively stable or responded. A statistically significant linear trend toward improvement was demonstrated across all 12 symptoms assessed. Median progression-free survival was significantly greater (P = .03) for the 38 patients who had durable diarrhea improvement than the 18 patients who did not (18.2 v 7.9 months, respectively). Adverse events (AEs) were reported in 96.7% (87 of 90) of patients. These AEs consisted primarily of reversible GI events (76 of 90), which could be caused in part by concomitant administration of amino acid solution given to reduce radiation exposure to the kidneys. There was one case each of grade 3 oliguria and grade 4 renal failure, each lasting 6 days.Conclusion:(90)Y-edotreotide treatment improved symptoms associated with malignant carcinoid among subjects with no treatment alternatives. Treatment was well-tolerated and had an acceptable expected AE profile.
Online Inquiry
Verification code
Inquiry Basket